Anti-TF Antibody (ALT-836) to Treat Septic Patients With Acute Lung Injury or Acute Respiratory Distress Syndrome

This study is ongoing, but not recruiting participants.

Sponsor:

Collaborator:

National Heart, Lung, and Blood Institute (NHLBI)

Information provided by (Responsible Party):

Altor Bioscience Corporation

ClinicalTrials.gov Identifier:

NCT00879606

First received: April 8, 2009

Last updated: March 15, 2013

Last verified: March 2013

History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study is ongoing, but not recruiting participants.
Estimated Study Completion Date:	October 2013
Primary Completion Date:	October 2012 (Final data collection date for primary outcome measure)

No publications provided by Altor Bioscience Corporation

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Morris PE, Steingrub JS, Huang BY, Tang S, Liu PM, Rhode PR, Wong HC. A phase I study evaluating the pharmacokinetics, safety and tolerability of an antibody-based tissue factor antagonist in subjects with acute lung injury or acute respiratory distress syndrome. BMC Pulm Med. 2012 Feb 16;12:5.

To Top